Melanoma trials in India

1 trial · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 4Not yet taking people in India
  A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India

  Where

  Bhubaneswar, Chennai, Mumbai, Nagpur, Nashik, Navi Mumbai, New Delhi, Pune

  Age

  12 years and over

  People

  40

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT07459543